In the Trypanosomatidae, trypanothione has subsumed many of the roles of glutathione in defense against chemical and oxidant stress. Crithidia fasciculata lacks glutathione S-transferase, but contains an unusual trypanothione S-transferase activity that is associated with eukaryotic translation elongation factor 1B (eEF1B). Here we describe the cloning, expression, and reconstitution of the purified ␣, , and ␥ subunits of eEF1B from Leishmania major. Individual subunits lacked trypanothione S-transferase activity. Only eEF1B, formed by reconstitution or co-expression of the three subunits, was able to conjugate a variety of electrophilic substrates to trypanothione or glutathionylspermidine, but not glutathione. In contrast to the C. fasciculata eEF1B, the L. major enzyme also displayed peroxidase activity against a variety of organic hydroperoxides. The enzyme showed no activity with hydrogen peroxide and greatest activity with linoleic acid hydroperoxide (1 unit mg ؊1 ). Kinetic studies suggest a ternary complex mechanism, with K m values of 140 M for trypanothione and 7.4 mM for cumene hydroperoxide and k cat ؍ 25 s ؊1 . Immunofluorescence studies indicate that the enzyme may be localized to the surface of the endoplasmic reticulum. These results suggest that, in addition to its role in protein synthesis, the Leishmania eEF1B may help protect the parasite from lipid peroxidation.Parasitic protozoa of the family trypanosomatidae cause disease and death throughout the tropical and subtropical world. Trypanosoma brucei infections are estimated to cause ϳ400,000 cases of sleeping sickness per year; Trypanosoma cruzi, the cause of Chagas' disease, chronically infects ϳ17 million people and Leishmania spp. are thought to cause 2 million cases of leishmaniasis per year. 1 Current chemotherapies for these diseases are, on the whole, ineffective and toxic (2, 3), whereas effective vaccines may never be developed. The development of effective treatments for these infections is therefore an urgent necessity.New anti-parasitic drugs can be developed from inhibitors of biochemical pathways that are essential for parasite survival but absent from the host. One such target is the thiol metabolism of trypanosomatids. Uniquely, this is dependent upon trypanothione (N 1 ,N 8 -bis(glutathionyl)spermidine or T[SH] 2 ) 2 (4), whereas their human hosts use glutathione ((␥-L-glutamyl-L-cysteinylglycine or GSH). Trypanothione is involved in protective processes, defending against oxidative stress through peroxidase systems (5), against reactive aldehydes through the glyoxalase system (6, 7), and against toxic xenobiotics through the trypanothione S-transferase (TST) (8). All these processes depend upon trypanothione being maintained in its dithiol form by trypanothione reductase. This NADPH-dependent flavoenzyme is essential to the trypanosomatids (9, 10) as, in these organisms, it is the only known route for the transfer of reducing equivalents from NADPH to low molecular mass thiols. In addition, because these parasites lack an...